Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Stock Rockets 23%: How To Trade Now?

This morning investors are expected to keep an eye on KalVista Pharmaceuticals Inc. (NASDAQ: KALV), after it emerged as one of the major gainers last Friday with gains of 23% for the day.

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

Last Thursday, the company hit the news cycle after it announced that a number of its extracts had been accepted for the GAF (HAEi Global Angioedema Forum) event scheduled from October 4-5 in Copenhagen, Denmark. In the news release, the company provided a detailed list of all the abstracts that had been accepted for the event. It may be a good move to take a look into some of those.

All nine abstracts would be presented through posters from 6 PM to 7 PM on October 4. One of these is the ‘Impact of Oral Sebetralstat on Anxiety Associated with Hereditary Angioedema Attacks in the Phase 3 KONFIDENT Trial’ and another one is ‘The Hereditary Angioedema (HAE) Attack Journey: A Conceptual Model of Patient Anxiety and On-Demand Treatment Burden During an HAE Attack’.

KalVista also listed out the names of the experts who would be highlighted in the concerned posters. It is going to be interesting to see if the KalVista stock continues to get traction in the days leading up to the event.